'Chemogenomics: Tools for protein families' and 'chemical genomics: Chemical and biological integration'

Pharmacogenomics

Volumn 4, Issue 1, 2003, Pages 15-18

  Nislow, Corey ^a,b   Giaever, Guri ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Signature Bioscience Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; FK 506 BINDING PROTEIN; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR; HYDROLASE INHIBITOR; IMATINIB; KINESIN; MONASTROL; NATURAL PRODUCT; PHOSPHOTRANSFERASE; TACROLIMUS; UNCLASSIFIED DRUG;

ANALYTIC METHOD; AUTOMATED LIGAND IDENTIFICATION SYSTEM; BIOINFORMATICS; BIOLOGY; CHEMICAL GENOMICS; CHEMICAL STRUCTURE; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; GENETIC TRANSFECTION; GENOMICS; HUMAN; MEDICAL LITERATURE; PHARMACOPHORE; PHENOTYPE; PROTEIN FAMILY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION PROCESS;

GENOMICS; PHARMACOGENETICS; PHENOTYPE; VARIATION (GENETICS);

EID: 0037232199     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.1.15.22579     Document Type: Conference Paper

References (10)

1. Rudek MA, Venitz J, Figg WD: Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 22, 705-720 (2002).
2. Hoelzer D, Gokbuget N, Ottmann OG: Gleevec for the treatment of chronic myelogenous leukaemia: US Food & Drug Administration regulatory mechanisms, accelerated approval and orphan drug status. Oncologist 7, 390-392 (2002).
3. Cohen MH, Moses ML, Pazdur R: Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia. Semin. Hematol. 39, 32-37 (2002).
4. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 46, 3-26 (2001).
5. Cohen SM, Lippard SJ: Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 67, 93-130 (2001).
6. Giaever G, Shoemaker DD, Jones TW et al.: Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21, 278-283 (1999).
7. Giaever G, Chu AM, Ni L et al.: Functional profiling of the saccharomyces cerevisiae genome. Nature 418, 387-391 (2002).
8. Kim JS, Pabo CO: Getting a handhold on DNA: design of poly-zinc-finger proteins with femtomolar dissociation constants. Proc. Natl. Acad. Sci. USA 95, 2812-2817 (1998).
9. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ: Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, eg5. J. Cell. Biol. 150, 978-988 (2000).
10. Wood KW, Cornwell WD, Jackson JR: Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. 1, 370-377 (2001).